Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma
Expert Review of Pharmacoeconomics & Outcomes Research · 05.11.2026 · 1-12
DOI: 10.1080/14737167.2026.2760014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 05.11.2026. Verfasst von Ying He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, China. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Joint Funds for the innovation of Science and Technology, Fujian province, Startup Fund for scientific research, Fujian Medical University, Natural Science Foundation of Ningde.
Abstract (Originalsprache)
BACKGROUND: Phase III trial NCT04560894 showed finotonlimab plus bevacizumab biosimilar SCT510 (FIN-BEV) improved survival over sorafenib in advanced hepatocellular carcinoma (HCC). However, the cost-effectiveness of FIN-BEV relative to sorafenib remains uncertain. This study evaluates the cost-effectiveness of FIN-BEV as a first-line treatment for advanced HCC from the perspective of the Chinese healthcare system, compared to sorafenib. METHODS: A partitioned survival model with three health states was built in TreeAge Pro 2022 using NCT04560894 data. Drug costs were calculated based on national bid-winning prices, while other costs and utility values were obtained from published Chinese literature. Sensitivity analyses were conducted to assess the robustness of the model. RESULTS: FIN-BEV yielded 2.43 QALYs at $66,740.79 versus sorafenib's 1.63 QALYs at $14,241.13. The incremental cost-effectiveness ratio was $65,717.80/QALY, exceeding the willingness-to-pay threshold of $27,906/QALY. The probability of FIN-BEV being cost-effective as a first-line treatment for advanced HCC was 0.2%. Key factors influencing the model results included the utility value of progression-free survival, the cost of SCT510, body weight, the utility value of progressive disease, and the cost of finotonlimab. CONCLUSION: From the perspective of the Chinese healthcare system, FIN-BEV does not represent a cost-effective first-line treatment for advanced HCC when compared to sorafenib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, China.
ORCID-Profile: Maojin You
Förderung
- Joint Funds for the innovation of Science and Technology, Fujian province
- Startup Fund for scientific research, Fujian Medical University
- Natural Science Foundation of Ningde
Zitieren
APA
He, Y., & You, M. (2026). Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research, 1-12. https://doi.org/10.1080/14737167.2026.2760014
Vancouver
He Y, You M. Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-12. doi:10.1080/14737167.2026.2760014
BibTeX
@article{He2026,
author = {He, Ying and You, Maojin},
title = {Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
pages = {1--12},
doi = {10.1080/14737167.2026.2760014}
}
EUVIMED